Skylands Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Skylands Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-25,200	Closed	-$17K	–	148
2020 Q4	$17K	Sell	25,200 -29,490	-54%	-$62.8K	﹤0.01%	123
2020 Q3	$123K	Hold	54,690	–	–	0.02%	120
2020 Q2	$196K	Sell	54,690 -600	-1%	-$2.17K	0.03%	108
2020 Q1	$210K	Hold	55,290	–	–	0.05%	103
2019 Q4	$166K	Buy	+55,290	New	+$144K	0.02%	116

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Skylands Capital's BMY.RT Position: Q1 2021 in Review

Skylands Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 25,200 shares — an estimated $17K sold.

Skylands Capital first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $210K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Skylands Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Skylands Capital sold 25,200 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $17K.
Skylands Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Skylands Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $210K in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Skylands Capital's 13F filing for Q1 2021, filed 4 May 2021.